Chemotherapy-induced peripheral neuropathy - epidemiology and pathogenesis

Area of Science:

• Neurology
• Oncology
• Pharmacology

Background:

• Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating neurologic complication.
• CIPN significantly impairs patients' quality of life (QoL), affecting daily activities and exercise.
• Neuropathy symptoms typically manifest in a stocking-glove distribution, starting in the lower extremities.

Purpose of the Study:

• To describe the clinical presentation and progression of chemotherapy-induced peripheral neuropathy.
• To highlight the impact of CIPN on patient quality of life.
• To discuss the implications of CIPN on chemotherapy treatment adherence and patient outcomes.

Main Methods:

• Review of clinical manifestations of CIPN.
• Analysis of patient-reported symptoms including numbness, tingling, and pain.
• Correlation of symptom severity with chemotherapy cycles.

Main Results:

• CIPN presents gradually, progressing proximally from lower limbs.
• Symptoms include sensory disturbances (numbness, tingling) and pain, worsening with cumulative chemotherapy exposure.
• While symptoms may improve upon chemotherapy cessation, complete resolution is not assured.

Conclusions:

• CIPN is a critical dose-limiting toxicity of neurotoxic chemotherapy agents.
• Management of CIPN is essential to maintain patient QoL and treatment continuity.
• Delayed or discontinued chemotherapy due to CIPN can negatively impact overall patient survival.